The Ebola Strain Nobody Had a Vaccine For Just Became a Global Emergency

The virus kept spreading. By mid-July, WHO counted 2,145 confirmed cases across the DRC, Uganda, and even a single imported case in France. As of July 19, DRC government figures showed 2,423 cases and 967 deaths across five provinces: Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo. What started in one province had fanned out across a region roughly the size of Texas.

The Scramble for Weapons That Don't Exist Yet

With no approved vaccine or treatment for Bundibugyo, the response has become a two-track race: deploy experimental therapies right now while building strain-specific vaccines for the months ahead.

On the treatment side, Mapp Biopharmaceutical's MBP134 is the lead candidate. It's a cocktail of two engineered monoclonal antibodies (think of them as lab-made proteins that latch onto the virus and neutralize it). MBP134 was designed to work against multiple Ebola species, not just Zaire. The U.S. government shipped doses to the DRC for both compassionate use and a formal clinical trial.

That trial, launched on July 2 in Bunia, Ituri Province, is a big deal. Run by the DRC's National Institute for Biomedical Research, the University of Oxford, and the Institute of Tropical Medicine in Antwerp (with WHO backing), it's testing four approaches: standard supportive care alone, care plus MBP134, care plus Gilead's remdesivir, and care plus both drugs combined. The goal is to measure survival at 28 days. Researchers plan to enroll 700 to 1,000 patients, which means definitive results could take months.

The Vaccine Pipeline: Lots of Candidates, Zero Approvals

On the vaccine front, BARDA (the U.S. Biomedical Advanced Research and Development Authority) put out a request for proposals to develop Bundibugyo-targeted vaccines using the same platform behind Ervebo, Merck's approved Zaire Ebola vaccine. Think of a platform like a chassis; you swap in a different engine (the Bundibugyo protein) and hope the vehicle still runs.

Meanwhile, the U.S. State Department committed $50 million to CEPI, the Coalition for Epidemic Preparedness Innovations, to accelerate lab work, clinical trials, and manufacturing. CEPI is already funding multiple shots on goal: Oxford and the Serum Institute of India are developing a viral-vector candidate called ChAdOx1-BDBV (up to $8.6 million in funding). IAVI has an rVSV-based candidate ($3.2 million). Moderna is working on an mRNA vaccine (up to $50 million from CEPI, the single largest commitment). Public Health Vaccines has another rVSV candidate ($1.9 million).

None of these candidates are anywhere close to deployment today.

Why This Matters Beyond the Outbreak

The Bundibugyo crisis is a stress test for everything the U.S. built after COVID. The National Biodefense Strategy calls for enrolling trial participants within 14 days of identifying a viable countermeasure. It also targets domestic capacity to produce enough vaccine doses within 130 days of a major biological event. Those are ambitious benchmarks, and this outbreak is measuring them in real time.

For biotech investors, the signal is clear: pan-ebolavirus antibodies like MBP134 and modular vaccine platforms (rVSV, mRNA, viral-vector) are the technologies with staying power. A narrowly targeted product works great until the wrong strain shows up. Broadly active therapies and swappable platforms hedge against that exact scenario.

The catch? Bundibugyo is a small, urgent market with no obvious commercial payoff. Development depends almost entirely on public funding, government procurement, and organizations like CEPI. If the trial data for MBP134 look good, it could build the case for permanent stockpiles of pan-ebolavirus treatments, a kind of insurance policy for future outbreaks.

The Clock Is Ticking

Right now, WHO still rates the risk in the DRC as "very high." The virus is reaching new health zones. Cases are climbing. And the only tools in the field are experimental, unproven, and limited in supply.

The post-COVID biodefense infrastructure was supposed to make moments like this faster and less chaotic. It's being put to the test against a virus that's been quietly waiting since 2007 for its turn on the world stage. Whether the response is fast enough will depend on how quickly trials produce answers and how fast factories can turn molecules into vials.

The fire is burning. The trucks are being built on the way to the scene.

One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie's $18B Drug

A tiny biotech called Oruka just posted psoriasis clearance rates that numerically beat AbbVie's $17.6 billion juggernaut Skyrizi, and it might only need one shot a year. Wall Street is losing its mind.